

08-31-06

LTJ-



PATENT
Attorney Docket No. 060230PCTUS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner :

In re application of : p18 IN STEM CELL MANIPULATIONS
Tao Cheng, M.D.

Group Art Unit No. :

Serial No.: 10/576,785 :

Filing Date: April 21, 2006

INFORMATION DISCLOSURE STATEMENT

Pittsburgh, Pennsylvania 15222

August 30, 2006

Commissioner for Patents
Box 1450
Alexandria, VA 22313-1450

Sir:

Applicant, in accordance with his duty of disclosure pursuant to 37 C.F.R. § 1.56, hereby advises the United States Patent and Trademark Office of the references listed on the accompanying form PTO/SB/08A and PTO/SB/08B (substitute for 1449A/PTO) *Information Disclosure Statement by Applicant*. A copy of each of the references cited therein is herewith enclosed.


"Express Mail" mailing label number EQ603942565US

Date of Deposit August 30, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Alexandria, VA 22313-1450

Applicant notes that although the cited references may be relevant to the examination of the above-referenced application, under 37 C.F.R. § 1.97(h), the filing of this *Information Disclosure Statement* "shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b)."


Respectfully submitted,


Christine R. Ethridge
Registration No. 30,577

Attorney for Applicant

Kirkpatrick & Lockhart Nicholson & Graham LLP
Henry W. Oliver Building
535 Smithfield Street
Pittsburgh, Pennsylvania 15222-2312

(412) 355-8619
(412) 355-6501 (FAX)



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 2				Complete if Known	
				Application Number	10/576,785
				Filing Date	April 21, 2006
				First Named Inventor	Cheng
				Art Unit	
				Examiner Name	Not yet assigned
				Attorney Docket Number	060230PCTUS

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/576,785
				Filing Date	April 21, 2006
				First Named Inventor	Cheng
				Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	060230PCTUS

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		DAVID S. FRANKLIN, VIRGINIA L. GODFREY, HAYOUNG LEE, GRIGORIY I. KOVALEV, ROBERT SCHOONHOVEN, SELINA CHEN-KIANG, LISHAN SU AND YUE XIONG, <i>CDK Inhibitors p18^{INK4c} and p27^{Kip1} Mediate Two Separate Pathways To Collaboratively Suppress Pituitary Tumorigenesis</i> , Genes & Development 12, (18) 2899-2911 (1998).	
		M.P. TSCHAN, U.R. PETERS, J.F. CAJOT, D.C. BETTICHER, M.F. FEY, AND A. TOBLER, <i>The Cyclin-Dependent Kinase Inhibitors p18^{INK4c} and p19^{INK4d} Are Highly Expressed In CD34⁺ Progenitor and Acute Myeloid Leukaemic Cells But Not In Normal Differentiated Myeloid Cells</i> , British Journal of Haematology, 644-651, (1999).	
		SHI-JIANG LU, CHENGSHI QUAN, FEI LI, LOYDA VIDA AND GEORGE R. HONIG, <i>Hematopoietic Progenitor Cells Derived From Embryonic Stem Cells: Analysis Of Gene Expression</i> , Stem Cells 20, 428-437, (2002).	
		YOUZHONG YUAN, HONGMEI SHEN, DAVID S. FRANKLIN, DAVID T. SCADDEN AND TAO CHENG, <i>In Vivo Self-Renewing Divisions Of Haematopoietic Stem Cells Are Increased In The Absence Of The Early G1-Phase Inhibitor, p18^{INK4c}</i> , Nature Cell Biology, Volume 6, Number 5, 436-442 (2004).	
		Tao Cheng, et al., "Transforming growth factor B1 mediates cell-cycle arrest of primitive hematopoietic cells independent of p21 ^{Cip1/Waf1} or P27 ^{Kip1} ", Blood, 15 December 2001, Vol. 98, No. 13, pp. 3643-3649.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.